Results 181 to 190 of about 28,869 (265)

Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum. [PDF]

Clin Pharmacokinet
Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson P, Myer L, Celum C, Heffron R, Coleman J, Davey DJ, Hendrix CW, Momper JD, Bies R, Scott RK.   +15 more
europepmc   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living with HIV Aged 50 Years and Older: A Retrospective Analysis of Naïve and Treatment-Experienced Individuals. [PDF]

Viruses
Trizzino M, Pipitò L, Di Figlia F, Bonura S, Zimmerhofer F, Cicero A, Gioè C, Cascio A.   +7 more
europepmc   +1 more source

BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV-Infected Patients. [PDF]

AIDS Res Treat
Pérez-Calvo F, Jover-Diaz F, Delgado-Sánchez E, Peris-García J, Bernabéu-Martínez MÁ.   +4 more
europepmc   +1 more source

Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide. [PDF]

AIDS Res Ther
Mounzer K, Osterman MD, Brunet L, Hsu RK, Pierone G, Fusco JS, Prata Menezes N, Gruber J, Lim T, Dunbar M, Fusco GP.   +10 more
europepmc   +1 more source

Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment. [PDF]

Open Forum Infect Dis
Díaz-García C, Serrano-Villar S, G García-Ruiz de Morales A, Güerri-Fernández R, Pérez-Somarriba J, Sánchez Palomino S, Suárez-García I, Hernández Gutiérrez C, Dalmau Juanola D, Moreno S, Moreno E, Martínez-Sanz J.   +11 more
europepmc   +1 more source

Improvement in kidney function in patients with chronic hepatitis B and chronic kidney disease after switching to tenofovir alafenamide fumarate: a systematic review with single arm meta-analysis. [PDF]

J Bras Nefrol
Pascoa Junior JG, Huntermann R, Gomes VMV, Mendes Filho FSM, Bertozzi JMV, Lins PRG.   +5 more
europepmc   +1 more source

Efficacy and safety of switching from lopinavir/ritonavir-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV: A multicenter retrospective study. [PDF]

Virol Sin
Fu J, Guo Y, Zheng G, Yang Z, Shi J, Yan D, Yu J, Sun L, Zhao H.   +8 more
europepmc   +1 more source

Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy. [PDF]

J Pediatric Infect Dis Soc
Natukunda E, Gaur AH, Deville JG, Kosalaraksa P, Strehlau R, Castaño E, Liberty A, Crowe S, Palaparthy R, Vieira VA, Kersey K, Rakhmanina N, Gordon CM.   +12 more
europepmc   +1 more source

Tenofovir alafenamide induced alopecia in an African American female: A case report to raise awareness on possible racial predisposition. [PDF]

JAAD Case Rep
Iloabuchi VC, Imhof RL, Wieland C, Zeuli JD, Katragadda S, Damodaran SS.   +5 more
europepmc   +1 more source